JACC Heart Failure Editor's Update, March 2019
MARCH 2018 SPECIAL ISSUE ON HEART FAILURE IN WOMEN
The incidence of heart failure is increasing, and women are disproportionately affected. Primary prevention can play an important role in decreasing this burden. There are significant gaps in sex-specific knowledge of risk factors for heart failure in women due to many factors including lack of representation of women in clinical trials. Melissa Daubert and Pamela Douglas summarize the evidence that does exist related to risk factors, examine epidemiological differences between men and women with heart failure, identify risk factors specific to HFrEF in women vs those specific to HFpEF, and present targets and prevention strategies.
Primary Prevention of Heart Failure in Women
Melissa A. Daubert and Pamela S. Douglas
With early diagnosis and treatment, breast cancer patients are living longer. Understanding the cardiovascular risk of adjuvant chemotherapy is critical to preventing adverse outcomes in this population. Adding trastuzumab to standard chemotherapy has significantly improved survival in HER2-positive breast cancer patients, but has been shown to induce symptomatic heart failure within the first two years after treatment. There is less certainty about long term risks, and observation suggests a greater risk than has been shown through clinical trials. Ann Banke et. al. looked at the risk of heart failure within 18 months of treatment and after 18 months following treatment to provide additional insight.
Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab
Ann Banke, Emil L. Fosbøl, et al
Are there differences in the use and outcomes of continuous flow left ventricular assist devices (CF-LVADs) among women versus men? Ersilia DeFilippis and colleagues analyzed outcomes from the database of the United Network for Organ Sharing to determine if there were disparities in use of CF-LVADs in women versus men listed for transplantation. They also looked at similarities and differences in risk profiles for women and men receiving mechanical bridge to heart transplantation and the likelihood of transplantation.
Sex-Related Differences in Use and Outcomes of Left Ventricular Assist Devices as Bridge to Transplantation
Ersilia M. DeFilippis, Lauren K. Truby, et al
Do men and women with HFpEF respond differently to spironolactone? Read this secondary analysis of TOPCAT data to learn more. Miranda Merrill and colleagues examined HFpEF patient characteristics for evidence of sex specific treatment response and looked for sex differences in primary and secondary outcomes in those treated with spironolactone.
Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial
Miranda Merrill, Nancy K. Sweitzer, et al.
JACC HEART FAILURE @ ACC.19
ACC.19 was an excellent opportunity to recognize outstanding papers by young authors, discuss some of our new and most popular features, including our Patient Perspective column and social media presence, and reflect on some of our best and most popular papers of 2018.
The 2018 recipients of the JACC: Heart Failure Young Author award are:
Kavita Sharma; Mentor: Stuart Russell. Randomized Evaluation of Heart Failure with Preserved Ejection Fraction Patients with Acute Heart Failure and Dopamine: The ROPA-DOP Trial. Dr. Sharma and colleagues examined the effectiveness of various strategies to achieve diuresis and halt the development of worsening kidney function in hospitalized HFpEF patients with acute heart failure.
Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine: The ROPA-DOP Trial
Kavita Sharma, Joban Vaishnav, et al.
Deanna N. Jones; Mentor: W. Gregory Hundley. Frequency of Transition From Stage A to Stage B Heart Failure After Initiating Potentially Cardiotoxic Chemotherapy. Dr. Jones and colleagues studied the rate and timing of progression to advanced stages of heart failure following potentially cardiotoxic chemotherapy.
Frequency of Transition From Stage A to Stage B Heart Failure After Initiating Potentially Cardiotoxic Chemotherapy
Deanna N. Jones, Jennifer H. Jordan, et al.
Best of 2018
As in prior years, along with the Editors-in-Chief of each of the JACC journals, I briefly discussed the papers our editorial team identified as the most impactful among the many outstanding articles published in 2018. Several of the papers we selected are listed below:
Antihyperglycemic Therapies to Treat Patients with Heart Failure and Diabetes Mellitus
Abhinav Sharma, Lauren B. Cooper, et al.
Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial
John J.V. McMurray, Piotr Ponikowski, et al, for the VIVIDD Trial Committees and Investigators
My Heart Failure Journey [Patient Perspective]
Association of Cardiac Rehabilitation With Decreased Hospitalizations and Mortality After Ventricular Assist Device Implantation
Justin M. Bachmann, Meredith S. Duncan, et al.
High-Sensitivity Cardiac Troponin and New-Onset Heart Failure: A Systematic Review and Meta-Analysis of 67,063 Patients With 4,165 Incident Heart Failure Events
Jonathan D.W. Evans, Stephen J.H. Dobbin, et al.
The Effect of Door-to-Diuretic Time on Clinical Outcomes in Patients With Acute Heart Failure
Jin Joo Park, Sun-Hwa Kim, et al.
What's One More Day? [Editor's Page]
Christopher M. O’Connor
Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials
Kishan S. Parikh, Kavita Sharma, et al.
African Americans Are Less Likely to Receive Care by a Cardiologist During an Intensive Care Unit Admission for Heart Failure
Khadijah Breathett, Wenhui G. Liu, et al.
CALL FOR PAPERS: HEART FAILURE IN THE ELDERLY
Heart failure is a significant global epidemic; however, in the elderly, there may be differences in treatment effects, treatment options, epidemiology, pathophysiology, risk factors, and outcomes. JACC: Heart Failure is focusing on the growing body of literature with a special issue on this topic. In line with our commitment to advance scientific understanding and patient care, we will publish a uniquely themed issue to highlight this emerging theme.
Topics spanning this theme will be considered, including epidemiology, diagnosis and prognosis, short- and long-term outcomes, clinical management, phenotyping, emerging therapies, comorbidities, the role of biomarkers, and other relevant issues.
How will this process work?
- We welcome papers addressing the broad topic of "Heart Failure in the Elderly" – these can be in the form of original research, clinical trials, meta-analysis, or position statements from societies or advocacy groups. Other formats will be considered if sufficiently rigorous and impactful.
- Interested authors should submit their papers via https://www.jaccsubmit-heartfailure.org on or before August 1, 2019. When entering manuscript information, please select "Heart Failure in the Elderly" from the "Special Issues" pull-down menu in the Keywords, Categories, Special Sections tab.
- We plan for the final publication to appear in the December 2019 issue of JACC: Heart Failure. Please see instructions to authors on the Journal webpage (https://heartfailure.onlinejacc.org).
- Accepted papers will also be displayed on the JACC: Heart Failure website in an “online before print” format.